ORPHA:94080
Non-functioning paraganglioma
Also known as: Non-secreting paraganglioma
Publications
41
36th percentile
Trials
0
Interventional, condition-specific
Researchers
199
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare neuroendocrine tumor arising from neural crest-derived paraganglion cells (most often in the para-aortic region at the level of renal hilia, organ of Zuckerkandl, thoracic paraspinal region, bladder, and carotid body) not associated with catecholamine secretion. These tumors are usually clinically silent and symptoms, if present, are nonspecific and depend on the location of the tumor. Association with certain cancer-predisposing syndromes, such as multiple endocrine neoplasia, neurofibromatosis type 1 or von Hippel lindau syndrome, may be observed.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019788
- UMLS:C4707263
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
41 matched papers (20 in last 10 years) Source
- Phenotype characterisedPresent
31 HPO annotations (e.g. Paraganglioma; Episodic hyperhidrosis; Cerebral hemorrhage) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 70 for broader category paraganglioma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
31
Associated phenotypes · MONDO:0019788
- Paraganglioma
- Episodic hyperhidrosis
- Cerebral hemorrhage
- Paraganglioma of head and neck
- Elevated urinary norepinephrine level
Showing 5 of 31 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
41
41 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
41 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
20 in the last 10 years · high confidence · 36th percentile (publications denominator)
Phrase hits: 41 · MeSH hits: 0
Who's working on it?
199
Distinct author names in 41 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01
- 02Jha A2 papers · 2020
Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
Papers in Europe PMC - 03Kimura N2 papers · 2018
Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.
Papers in Europe PMC - 04Abdellatif K1 paper · 2017
Service d'urologie B, CHU Ibn Sina, Faculté de Médecine et de Pharmacie de Rabat- Université Mohamed V- Maroc.
Papers in Europe PMC - 05Aboutaib R1 paper · 2015
Service d'Urologie du CHU Ibn Rochd de Casablanca, Maroc.
Papers in Europe PMC - 06Abrar FN1 paper · 2025
Addis Ababa University, School of Medicine, Department of Surgery, Urology Unit, Ethiopia. Electronic address: fadil.nuredin@aau.edu.et.
Papers in Europe PMC - 07Ahmed A1 paper · 2011Papers in Europe PMC
- 08Ahmed AA1 paper · 2017
Service d'urologie B, CHU Ibn Sina, Faculté de Médecine et de Pharmacie de Rabat- Université Mohamed V- Maroc.
Papers in Europe PMC - 09Alemu TN1 paper · 2025
Addis Ababa University, School of Medicine, Department of Surgery, Urology Unit, Ethiopia.
Papers in Europe PMC - 10Allievi A1 paper · 2006
Unidad A de Clínica Medica, Servicio de Cirugía General, Sección Endocrinología, Servicio de Gastroenterología, Servicio de Patología, Hospital Juan A. Fernández, Buenos Aires. hdelle@intramed.net
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 70 trials are registered for paraganglioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
70 interventional trials matched paraganglioma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: paraganglioma
70
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06377033·RECRUITING·Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Conditions: Genetic Predisposition · Paraganglioma · Pheochromocytoma · ALS·Matched via name phrase
- NCT05069220·RECRUITING·18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Conditions: Neuroendocrine Tumor · Neuroblastoma · Pheochromocytoma · Paraganglioma·Matched via name phrase
- NCT06683846·RECRUITING·Ivonescimab in the Treatment of Multiple Advanced Tumors
Conditions: Pheochromocytoma/Paraganglioma · Rhabdomyosarcoma · Paget Disease, Extramammary · Renal Angiomyolipoma·Matched via name phrase
- NCT07661420·NOT YET RECRUITING·211At-MABG in Adults With Advanced Neuroendocrine Cancers
Conditions: Pheochromocytoma · Paraganglioma · Neuroendocrine Tumors · Medullary Thyroid Cancer·Matched via name phrase
- NCT04119024·RECRUITING·Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Conditions: Metastatic Malignant Solid Neoplasm · Metastatic Melanoma · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · Pathologic Stage IV Cutaneous Melanoma AJCC v8·Matched via name phrase
- NCT07680205·RECRUITING·An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
Conditions: Pheochromocytoma and Paraganglioma (PPGL) · Pheochromocytoma Malignant · Pheochromocytoma, Metastatic · Pheochromocytoma/Paraganglioma·Matched via name phrase
- NCT03206060·RECRUITING·Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Conditions: Pheochromocytoma · Paraganglioma · Neuroendocrine Tumors · Neuroendocrine Neoplasms·Matched via name phrase
- NCT05702944·RECRUITING·The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
Conditions: Pheochromocytoma · Paraganglioma · Adrenalectomy; Status · Adrenergics Causing Adverse Effects in Therapeutic Use·Matched via name phrase
- NCT04081701·RECRUITING·68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Conditions: CNS Tumors · Meningioma · Esthesioneuroblastoma · Hemangioblastoma·Matched via name phrase
- NCT07714551·NOT YET RECRUITING·Zanzalintinib in Unresectable and Progressive MPGGs
Conditions: Pheochromocytoma · Paraganglioma·Matched via name phrase
- NCT07288931·RECRUITING·Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma/Paraganglioma (PPGL)·Matched via name phrase
- NCT06121271·NOT YET RECRUITING·Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
Conditions: Bronchial and Thymic Neuroendocrine Tumour · Paraganglioma/ Phaeochromocytoma · Medullary Thyroid Carcinoma · Those Requiring Repeat Peptide Receptor Radionuclide Therapy·Matched via name phrase
- NCT07282587·RECRUITING·Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Conditions: Advanced Pheochromocytoma and Paraganglioma · PCPG·Matched via name phrase
- NCT05636540·RECRUITING·In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma · Paraganglioma·Matched via name phrase
- NCT07743138·NOT YET RECRUITING·STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Conditions: Phase II · Ivonescimab · Evaluate · Unresectable/Metastatic Adrenocortical Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Non-functioning paraganglioma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Non-functioning paraganglioma" OR "Non-secreting paraganglioma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Non-functioning paraganglioma" OR "Non-secreting paraganglioma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"paraganglioma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T04:37:16.590Z
